BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24630733)

  • 1. Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control.
    Suh S; Joung JY; Jin SM; Kim MY; Bae JC; Park HD; Lee MS; Lee MK; Kim JH
    Diabetes Metab; 2014 Sep; 40(4):272-7. PubMed ID: 24630733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?
    Paul SK; Holman RR
    Diabet Med; 2017 Sep; 34(9):1284-1290. PubMed ID: 28477414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
    Vos FE; Schollum JB; Coulter CV; Manning PJ; Duffull SB; Walker RJ
    Nephrology (Carlton); 2012 Feb; 17(2):182-8. PubMed ID: 21883672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
    Konya J; Ng JM; Cox H; Cooke M; Lewis N; Bhandari S; Atkin SL; Kilpatrick ES
    Diabet Med; 2013 Oct; 30(10):1250-4. PubMed ID: 23758176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients.
    Sun J; Dou JT; Wang XL; Yang GQ; Lü ZH; Zheng H; Ma FL; Lu JM; Mu YM
    Chin Med J (Engl); 2011 Nov; 124(22):3641-5. PubMed ID: 22340217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
    Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
    Moses AC; Raskin P; Khutoryansky N
    Diabet Med; 2008 Feb; 25(2):200-5. PubMed ID: 18290862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
    Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
    Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
    Bao YQ; Zhou J; Zhou M; Cheng YJ; Lu W; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):564-8. PubMed ID: 20082624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.
    Zelnick LR; Batacchi ZO; Ahmad I; Dighe A; Little RR; Trence DL; Hirsch IB; de Boer IH
    Diabetes Care; 2020 Oct; 43(10):2379-2387. PubMed ID: 32788282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic instability is an underestimated problem in Type II diabetes.
    Praet SF; Manders RJ; Meex RC; Lieverse AG; Stehouwer CD; Kuipers H; Keizer HA; van Loon LJ
    Clin Sci (Lond); 2006 Aug; 111(2):119-26. PubMed ID: 16613586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic markers and all-cause mortality in older adults with and without diabetes: the Atherosclerosis Risk in Communities (ARIC) study.
    Rooney MR; Tang O; Pankow JS; Selvin E
    Diabetologia; 2021 Feb; 64(2):339-348. PubMed ID: 32990802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.
    Chon S; Lee YJ; Fraterrigo G; Pozzilli P; Choi MC; Kwon MK; Chin SO; Rhee SY; Oh S; Kim YS; Woo JT
    Diabetes Technol Ther; 2013 Jun; 15(6):455-60. PubMed ID: 23617251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.
    Monnier L; Colette C; Owens DR
    Diabetes Metab Res Rev; 2009 Jul; 25(5):393-402. PubMed ID: 19437415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes.
    Bao YQ; Zhou M; Zhou J; Lu W; Gao YC; Pan XP; Tang JL; Lu HJ; Jia WP
    Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):50-4. PubMed ID: 21083700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus.
    Suzuki S; Koga M; Amamiya S; Nakao A; Wada K; Okuhara K; Hayano S; Sarhat AR; Takahashi H; Matsuo K; Tanahashi Y; Fujieda K
    Diabetologia; 2011 Sep; 54(9):2247-53. PubMed ID: 21644010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments.
    Won HK; Kim KJ; Lee BW; Kang ES; Cha BS; Lee HC
    Diabet Med; 2012 Jan; 29(1):74-9. PubMed ID: 21781151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HbA₁(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study.
    Borg R; Kuenen JC; Carstensen B; Zheng H; Nathan DM; Heine RJ; Nerup J; Borch-Johnsen K; Witte DR;
    Diabetologia; 2011 Jan; 54(1):69-72. PubMed ID: 20886203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.